ASO-mediated reduction of toxic C9orf72 dipeptide repeat proteins in ALS/FTD
🧪 Overview
Antisense oligonucleotides targeting expanded GGGGCC repeats in C9orf72 offer the strongest therapeutic hypothesis by simultaneously addressing three pathogenic mechanisms: C9orf72 haploinsufficiency, RNA foci sequestration, and toxic dipeptide repeat protein accumulation. The tofersen precedent validates the ASO modality for motor neuron disease, and ongoing clinical trials (NCT03626012) provide immediate translational momentum. Critical risks include cortical delivery limitations for FTD pathology and potential immune dysfunction from C9orf72 loss.
🧬 Mechanism
⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — C9ORF72
No curated PDB or AlphaFold mapping for C9ORF72 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for C9orf72.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |